Effects of Uremia on Brachial Plexus Electrophysiology and Brachial Plexus Block

Nanjing Medical University

Status: Not yet enrolling

Conditions: Electrical Stimulation of Nerves Produces Muscle Reflexes

Treatments: Device: Neural Stimulator

Study type: Interventional

Funder types: Other

Identifiers

NCT06931756

KY20250123-09

Details and patient eligibility

About

As a late stage of renal failure, uremia not only leads to severe impairment of renal function in patients, but also often leads to a variety of complications, among which multiple peripheral neuropathy is particularly common. This lesion is mainly caused by the combination of multiple mechanisms, such as the accumulation of uremic toxins, electrolyte disorder, nutrient deficiency and factors related to hemodialysis. Therefore, it is important clinical significance to deeply explore the effects of uremia on electrophysiological properties and nerve block of brachial plexus.

At present, there are relatively few studies on the effects of uremia on the brachial plexus, especially the prospective parallel cohort studies on its electrophysiological properties and nerve block. As a new anesthetic technique, ultrasound-guided axillary brachial plexus block has the advantages of precise positioning, scientific administration, reducing complications and improved safety, but the application effect and safety in uremic patients still need to be further verified.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Uremia group [group U]

  1. Patients aged 18 years and older
  2. ASA classification I-IV
  3. BMI 18.5-29.9
  4. Patients with uremia planning to undergo forearm or hand surgery
  5. Diagnostic criteria: Patients must meet the internationally recognized diagnostic criteria for uremia and require hemodialysis
  6. Informed consent: Patients or their legal representatives must sign an informed consent form, agreeing to participate in this study and undergo related examinations and treatments

• Non-uremia group [Group N]

  1. Patients aged 18 years and older
  2. ASA classification I-IV
  3. BMI 18.5-29.9
  4. Patients planning to undergo forearm or hand surgery
  5. In addition to possibly having diabetes, patients should not have any other diseases that could cause peripheral neuropathy
  6. The patient or their legal representative must sign an informed consent form, agreeing to participate in this study and receive the relevant examinations and treatments

Exclusion criteria

• Individuals allergic to study medications (such as ropivacaine)
• Those with contraindications to local anesthesia or nerve blockades, such as coagulation disorders, infections, etc.
• Those with severe cardiovascular or respiratory diseases
• Those unable to comply with study requirements, such as cognitive impairment, mental disorders, etc.
• Pregnant women

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

Uremia group (U group)

Experimental group

Description:

1. Patients aged 18 years and above, ASA classification I-IV, BMI 18.5-29.9, planning to undergo forearm or hand surgery. 2. Diagnostic criteria: Patients who meet the internationally recognized diagnostic criteria for uremia and require hemodialysis. 3. Informed consent: Patients or their legal representatives must sign an informed consent form, agreeing to participate in this study and undergo related examinations and treatments.

Treatment:

Device: Neural Stimulator

Non-uremia group (Group N)

Experimental group

Description:

1. According to the Propensity Score Matching (PSM) design for the control group, select patients aged 18 years or older, ASA classification I to IV, matched with patients in the U group in terms of age, gender, and BMI within the corresponding group, who are planned to undergo forearm or hand surgery. In addition to possibly having diabetes, patients should not have any other diseases that could cause peripheral neuropathy. 2. Informed consent: Similar to the uremic patient group, an informed consent form must be signed.

Treatment:

Device: Neural Stimulator